Stockhead

Health Check: Cancer assay developer BCAL finds quickest, breast route to the US

The developer of a non-invasive blood-based assay, BCAL hopes to enter the US market by the quicker lab-developed test route.
PR Newswire

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic ...

Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial ...
The Lancet

Moving beyond R-CHOP in large B-cell lymphoma

Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...
Wareable

Garmin Fenix 8 vs. Epix Pro vs. Epix (Gen 2): What we recommend

Despite it being over a year since the release of the Garmin Fenix 8, the older Epix and Epix Pro remain two of the best alternatives. The brand consolidated its lineup considerably with the Fenix 8 ...
Open Heart

Acute effects of percutaneous coronary intervention on neutrophil activation and maturity markers in coronary and peripheral circulation

Background Acute inflammatory responses during and after percutaneous coronary intervention (PCI) are associated with subsequent cardiovascular event risk, but limited data exist on acute immune cell ...
The Lancet

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study

mNational Institute for Health Research National Commercial Research Delivery Centre, Bradford, UK nNational Institute for Health Research Manchester Biomedical Research Centre, Manchester University ...